|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
82,625,000 |
Market
Cap: |
133.85(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.59 - $5.45 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
223,100 |
223,100 |
Total Sell Value |
$0 |
$0 |
$449,770 |
$449,770 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Anicetti Vincent R |
Chief Operating Officer |
|
2019-08-14 |
4 |
OE |
$2.50 |
$6,251 |
D/D |
2,500 |
21,810 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2019-07-15 |
4 |
AS |
$19.20 |
$48,000 |
D/D |
(2,500) |
19,310 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2019-07-15 |
4 |
OE |
$2.50 |
$6,251 |
D/D |
2,500 |
21,810 |
|
- |
|
Healy James |
Director |
|
2019-07-02 |
4 |
AS |
$22.61 |
$3,617,600 |
I/I |
(160,000) |
1,933,221 |
|
- |
|
Healy James |
Director |
|
2019-06-28 |
4 |
AS |
$22.05 |
$4,410,000 |
I/I |
(200,000) |
2,093,221 |
|
- |
|
Healy James |
Director |
|
2019-06-20 |
4 |
AS |
$21.37 |
$6,777,068 |
I/I |
(317,130) |
2,293,221 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2019-06-19 |
4 |
AS |
$20.00 |
$77,587 |
D/D |
(3,826) |
11,513 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2019-06-19 |
4 |
OE |
$10.05 |
$31,748 |
D/D |
3,159 |
14,672 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2019-06-18 |
4 |
AS |
$19.31 |
$57,926 |
D/D |
(3,000) |
12,180 |
|
- |
|
Wahlstrom Mats |
Director |
|
2019-05-31 |
4 |
A |
$0.00 |
$0 |
I/I |
98,152 |
318,066 |
|
- |
|
Wahlstrom Mats |
Director |
|
2019-05-31 |
4 |
D |
$0.00 |
$0 |
I/I |
(178,528) |
0 |
|
- |
|
Lanfear Dennis M |
President & CEO |
|
2019-05-30 |
4 |
S |
$19.49 |
$631,282 |
I/I |
(32,398) |
1,284,184 |
|
- |
|
Healy James |
Director |
|
2019-05-22 |
4 |
AS |
$20.69 |
$5,335,330 |
I/I |
(257,870) |
2,610,351 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2019-03-20 |
4 |
S |
$14.92 |
$44,762 |
D/D |
(3,000) |
13,185 |
|
- |
|
Lanfear Dennis M |
President and CEO |
|
2019-01-11 |
4 |
D |
$12.37 |
$221,015 |
D/D |
(17,867) |
125,017 |
|
- |
|
Lanfear Dennis M |
President and CEO |
|
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
50,265 |
142,884 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2019-01-11 |
4 |
D |
$12.37 |
$77,894 |
D/D |
(6,297) |
16,185 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,685 |
22,482 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2019-01-11 |
4 |
D |
$12.37 |
$73,181 |
D/D |
(5,916) |
17,474 |
|
- |
|
Vexler Vladimir |
Chief Scientific Officer |
|
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,562 |
23,390 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2019-01-11 |
4 |
D |
$12.37 |
$79,217 |
D/D |
(6,404) |
17,295 |
|
- |
|
Anicetti Vincent R |
Chief Operating Officer |
|
2019-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
16,997 |
23,699 |
|
- |
|
Viret Jean-Frederic |
Chief Financial Officer |
|
2018-09-21 |
4 |
OE |
$13.50 |
$9,990 |
D/D |
740 |
4,519 |
|
- |
|
Finck Barbara K |
Chief Medical Officer |
|
2018-09-10 |
4 |
AS |
$18.58 |
$32,699 |
D/D |
(1,760) |
37,043 |
|
- |
|
Finck Barbara K |
Chief Medical Officer |
|
2018-09-10 |
4 |
OE |
$1.42 |
$2,499 |
D/D |
1,760 |
38,803 |
|
- |
|
312 Records found
|
|
Page 7 of 13 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|